|
Originally published In Press as doi:10.1074/jbc.M000907200 on July 18, 2000
J. Biol. Chem., Vol. 275, Issue 40, 31226-31232, October 6, 2000
TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular
Matrix*
Wei-Hsuan
Yu ,
Shuan-su C.
Yu,
Qi
Meng§,
Keith
Brew, and
J.
Frederick
Woessner Jr.¶
From the Department of Biochemistry and Molecular Biology,
University of Miami School of Medicine, Miami, Florida 33101
Received for publication, February 3, 2000, and in revised form, July 7, 2000
 |
ABSTRACT |
Of the four known tissue inhibitors of
metalloproteinases (TIMPs), TIMP-3 is distinguished by its tighter
binding to the extracellular matrix. The present results show that
glycosaminoglycans such as heparin, heparan sulfate, chondroitin
sulfates A, B, and C, and sulfated compounds such as suramin and
pentosan efficiently extract TIMP-3 from the postpartum rat uterus.
Enzymatic treatment by heparinase III or chondroitinase ABC also
releases TIMP-3, but neither one alone gives complete release. Confocal
microscopy shows colocalization of heparan sulfate and TIMP-3 in the
endometrium subjacent to the lumen of the uterus. Immunostaining of
TIMP-3 is lost upon digestion of tissue sections with heparinase III and chondroitinase ABC. The N-terminal domain of human TIMP-3 was
expressed and found to bind to heparin with affinity similar to that of
full-length mouse TIMP-3. The A and B -strands of the N-terminal
domain of TIMP-3 contain two potential heparin-binding sequences rich
in lysine and arginine; these strands should form a double track on the
outer surface of TIMP-3. Synthetic peptides corresponding to segments
of these two strands compete for heparin in the DNase II binding assay.
TIMP-3 binding may be important for the cellular regulation of activity
of the matrix metalloproteinases.
 |
INTRODUCTION |
The extracellular matrix
(ECM)1 provides mechanical
support to cells and regulates signals reaching the cell that govern
cell localization, differentiation, proliferation, and apoptosis.
Components of the ECM, particularly the glycosaminoglycans (GAGs), are
able to sequester bioactive molecules such as growth factors (1), proteases (2), and inhibitors. Turnover of the ECM is a highly regulated process necessary for movement of cells and for release of
growth factors. Matrix metalloproteases (MMPs) are believed to be key
participants in this remodeling; there are at least 20 MMPs, all able
to digest various ECM components (3, 4).
The MMPs, in turn, are regulated by tissue inhibitors of
metalloproteinases or TIMPs. The major function of the TIMPs is to inhibit MMPs; any imbalance in which the activities of MMPs outweigh the TIMP levels will favor tissue destruction and pathological processes (5, 6). The TIMPs also possess growth stimulatory and
regulatory activities (7, 8). The four members of the TIMP family all
have similar secondary structures of six loops stabilized by six highly
conserved disulfide bonds. The TIMPs all bind tightly, albeit with
widely varying affinity, to the various MMPs. The x-ray structure (9)
shows that the N-terminal cysteine chelates the active site zinc. TIMPs
have N- and C-terminal domains, each with three loops. The N-terminal
domain of TIMP-1 folds readily and displays full inhibitory activity
(10).
TIMP-3 has several features that distinguish it from the other TIMPs.
First, it is the only TIMP to bind tightly to the ECM: it was first
observed as a transformation-sensitive protein bound to the ECM of
chick embryo fibroblasts (11) and extractable with SDS or guanidine.
This protein was subsequently shown to be TIMP-3 (12). Second, TIMP-3
is the only TIMP to inhibit members of the ADAM (a
disintegrin and metalloprotease
domain) family such as tumor necrosis factor- -converting enzyme
(13); this may account for its ability to induce apoptosis (14). It is the only TIMP to inhibit shedding of L-selectin (15) and
interleukin-6 receptors (16). Third, TIMP-3 is the only TIMP directly
implicated in a disease process: Ser-Cys mutants of TIMP-3 accumulate
in Bruch's membrane of the eye and cause Sorsby's fundus dystrophy (17). TIMP-3 also promotes the detachment of transformed cells from the
ECM (18) and is involved in the formation, branching, and expansion of
epithelial tubes and in regulating trophoblast invasion of the uterus
(19).
The present study is concerned with the mechanism of binding of TIMP-3
to the extracellular matrix. We recently reported that matrilysin could
bind to heparan sulfate in rat uterine tissues (2). In this work, it
was noted that heparin not only extracted matrilysin from the tissue,
but also solubilized TIMP-3. The present results indicate that heparan
sulfate and other sulfated glycosaminoglycans may be responsible for
the binding of TIMP-3 to the ECM.
 |
EXPERIMENTAL PROCEDURES |
Extraction of TIMP-3--
Uteri were collected 1 day postpartum
from Harlan Sprague-Dawley rats (Harlan), weighed (~2 g), washed 3×
with cold 50 mM Tris, pH 7.5, 0.03% sodium azide, and
homogenized in 20 ml of this buffer containing 0.1% Triton X-100 with
a Polytron for 6 min at 4 °C. The mixture was centrifuged at 11,000 rpm for 20 min. The pellet was washed 2× and resuspended in the same
volume of cold 50 mM Tris, pH 7.5, 0.03% sodium azide, 50 µM Z-Phe-chloromethyl ketone, 50 µM aminoethyl-benzenesulfonyl fluoride. The suspension was divided at 0.5 ml per tube. Extractants (50 µl, Sigma) were added
to a final concentration of 0.2 mg/ml of the various GAGs and 2 mg/ml
of pentosan and suramin. Extraction at 4 °C for 30 min was followed
by centrifugation at 14,000 rpm for 10 min. For the heat extraction
procedure, see Ref. 20. To destroy TIMPs, control extracts were reduced
with 5 mM dithiothreitol for 25 min, 24 °C, and thiol
groups were blocked with 10 mM iodoacetic acid. For the
heparinase III (Flavobacterium heparinum, heparitinase I,
Sigma) and chondroitinase ABC (Sigma) digestion, pellets were resuspended in 50 mM Tris, pH 7.5, 0.03% sodium azide, 5 mM CaCl2, 10 µM
ZnCl2, 50 µM Z-Phe-chloromethyl
ketone, and 50 µM aminoethyl-benzenesulfonyl fluoride and incubated with 0.2 unit of enzyme/ml at 37 °C
for 18 h. Controls were incubated without added enzyme to check
for endogenous activity.
Reverse Zymography--
Components for 12.5% SDS-polyacrylamide
gel were mixed with gelatin (final concentration 1 mg/ml) and a
proprietary mixture of gelatinases (University Technology
International, Calgary) and cast as gels. Extracts containing
TIMPs were electrophoresed, and the gels were then washed 3× with
2.5% Triton X-100/50 mM Tris/5 mM
CaCl2/0.03% azide and 3× with 50 mM Tris, pH
7.5, 5 mM CaCl2, 50 µM
Z-Phe-chloromethyl ketone, and 10 mM
phenylmethylsulfonyl fluoride. The gels were incubated in this latter
mixture at 37 °C for 18 h and stained with Coomassie Blue. The
blue gelatin staining was cleared by gelatinase action except where
TIMP bands blocked this activity. Marker TIMPs (mouse) were also
obtained from the University Technology International, Calgary.
Confocal Microscopy--
Frozen tissue sections (5 µm) from
26- to 32-h postpartum rat uterus were air-dried and soaked in 95%
ethanol for 10 min. Sections were prefixed with 100% methanol for 20 min and rinsed 3× with PBS. For the pretreated group, some sections
were washed with 100 µl of heparin (20 mg/ml) for 1 h at
24 °C or digested for 18 h in a moist chamber at 24 °C with
heparinase III, or chondroitinase ABC, or a combination of the two.
These enzymes (0.2 unit/ml) were used in 50 mM acetate
buffer, pH 6.5, containing 0.1 M ZnCl2, 5 mM CaCl2, 5 mM MgCl2,
10 mM phenylmethylsulfonyl fluoride, 0.05% sodium azide,
and the following inhibitors at 0.1 mM: Z-Phe-chloromethyl ketone, tosyl-Phe-chloromethyl ketone, tosyl-Leu-chloromethyl ketone,
antipain, and BB-94 (British BioTech Pharmaceuticals Ltd.). Control
sections were treated with the same mixture without enzyme. The
sections were rinsed twice with PBS.
Sections that were not pretreated were postfixed for 5-10 min with
3.7% paraformaldehyde, rinsed with PBS, and blocked with 10%
heat-inactivated normal rabbit serum at 24 °C in PBS for 40 min. They were then exposed to goat polyclonal antibody against human
TIMP-3 (Santa Cruz Biotechnology, Santa Cruz, CA) and mouse monoclonal
antibody (IgM) against heparan sulfate (Sagaku) for 1 h. The
TIMP-3 antibody was raised against the C-terminal 20 amino acids and
recognized both rat and human TIMP-3. Sections were washed 3× in PBS.
Primary antibodies were reacted with a mixture in blocking reagent of
rabbit anti-goat IgG polyclonal antibody conjugated to fluorescein
isothiocyanate and rabbit anti-mouse IgM polyclonal antibody conjugated
to Texas Red (both from Jackson ImmunoResearch Laboratories). Sections
were washed 3× in PBS for a total of 45 min. Controls included
sections in which the first antibody was omitted, sections treated only
with goat anti-human TIMP-3 followed by rabbit anti-mouse IgM antibody,
and sections treated with mouse anti-heparan sulfate followed by rabbit
anti-rabbit IgG antibody (to show absence of cross-species reaction).
Washed sections were covered with SlowFade mounting solution (Molecular
Probes, Eugene, OR), and a coverslip was applied. Sections were
analyzed with a Zeiss confocal laser scanning microscope (LSM 510)
equipped with a 25-milliwatt krypton-argon laser and a 10-milliwatt
helium-neon laser. Excitation was at 488 nm and emission at 530 and 590 nm for fluorescein isothiocyanate and Texas Red, respectively. Images
were captured at 0.5-µm increments along the Z axis and
converted to composite images by LSM 510 software.
Recombinant TIMP-3--
BHK cells transfected with mouse TIMP-3
(mT3PNUT.BHK, University Technology International, Calgary) were
grown at 37 °C in Dubecco's modified Eagle's medium/nutrient
mixture F12 (Life Technologies, Inc.) containing 5% fetal calf serum
and 1% penicillin and streptomycin. Conditioned medium (50 ml) was
collected from 75-cm2 cell cultures confluent for 3-4
days. Medium (1 ml) from BHK-TIMP-3 cell cultures was mixed with 4 ml
of buffer suspension of 0.5 mg of heparin-agarose beads (Sigma, H-0402)
and stirred at room temperature for 4 h. The mixture was poured in
a small column then washed with 50 mM Tris, pH 7.5, plus
0.15 M NaCl. Stepwise elution was then carried out using
increasing amounts of NaCl or heparin in Tris buffer
Expression of N-TIMP-3 in E. coli--
Human TIMP-3 cDNA
from a placental cDNA library was kindly provided by Dr. H. Nagase,
University of Kansas Medical Center. A set of primers,
5'-AGTCATATGTGCACATGCTCG3-' (forward) and 5'-GCGGCCGCGTTACAACCCAGGTG-3' (reverse), was used in a one-step polymerase chain reaction to amplify
the cDNA insert encoding N-terminal TIMP-3 (residues
Cys1-Asn121). The amplified insert was digested
by NdeI and NotI and ligated into pET21b vectors
(Invitrogen Inc.). The ligation reaction mixture was used to transform
the Escherichia coli DH5 competent cells. Plasmid DNA
from positive clones was purified using the Qiagen kit and digested by
NotI and NdeI at 37 °C for 3 h. The
correct clone was confirmed by DNA sequencing and used to transform
into the expression host E. coli BL21(DE3). Cells containing
pET3a-N-TIMP-3 were grown in 3 ml of LB/ampicillin medium at 37 °C
overnight then inoculated into 1- to 6-liter batches. When
A600 reached 0.6-0.8, the culture was induced
with isopropyl- -D-thiogalactopyranoside (0.4 mM) for protein expression. Cells were grown for another 3 h and harvested by centrifugation.
Purification of N-TIMP-3--
N-TIMP-3 was expressed as a fusion
protein with a C-terminal His tail. Inclusion bodies were dissolved in
50 ml of loading buffer (5 mM imidazole, 0.5 M
NaCl, 20 mM Tris-HCl, pH 7.9, 6 M guanidine)
and centrifuged at 10,000 rpm for 40 min. The supernatant was loaded
onto a Ni-NTA column (7 × 80 mm, Qiagen) equilibrated with
loading buffer. The column was washed at room temperature with 60 mM imidazole, 0.5 M NaCl, 8 M urea,
20 mM Tris-HCl, pH 7.9, then eluted with 500 mM
imidazole, 0.25 M NaCl, 8 M urea, 10 mM Tris-HCl, pH 7.9. Fractions from the Ni-NTA column were analyzed by SDS-polyacrylamide gel electrophoresis.
Folding N-TIMP-3--
Recombinant N-TIMP-3 in 8 M
urea, 0.15 M NaCl, 50 mM Tris, pH 7.5, 0.05%
Triton X-100, and 5 mM dithiothreitol was diluted 1:10 in
folding buffer A (20 mM acetate buffer, pH 5.6, 0.15 M NaCl, 5 mM dithiothreitol, and 0.05% Triton
X-100). Heparin-agarose beads (Sigma) were suspended in 50 mM Tris, 0.15 M NaCl, pH 7.8. A mixture of 1 ml
of TIMP-3 plus 4-ml beads (0.5 mg) was transferred into 6-kDa cut-off
dialysis tubing and dialyzed against folding buffer B (50 mM Tris, 0.15 M NaCl, pH 7.8, 0.05% Triton,
0.03% sodium azide, and 10 mM cystamine), 50 ml, with
three changes. In the final dialysis, folding buffer C (50 mM Tris, 0.15 M NaCl, pH 7.8, 0.05% Triton,
0.03% sodium azide) was used. The mixture was poured into a small
column then washed with 50 mM Tris, pH 7.5, plus 0.2 M NaCl. Elution of folded N-TIMP-3 was then carried out
using increasing amounts of NaCl or heparin in Tris buffer.
DNase II-based Homogeneous Heparin Binding Assay--
In this
assay, binding of heparin to DNase II was assessed (21).
Competitive test compounds were added at 4 °C for 20 min in pH 4.8 acetate buffer + 5 mM dithiothreitol; then substrate was
added for digestion at 37 °C. Heparin concentration was adjusted to
inhibit DNase II activity by 90%; compounds binding heparin reversed
this inhibition. The percentage inhibition observed in the presence of
heparin and added test species was plotted versus log
concentration to yield the dose-response curve for the given species.
Several peptides from the A and B strands of TIMP-3 and RHAMM401-411 (a heparin-binding peptide from the Receptor
for Hyaluronic Acid-Mediated Mobility) were synthesized (Genemed).
 |
RESULTS |
Sulfated Glycosaminoglycans Extract TIMP-3 from Postpartum Rat
Uterus Tissue--
Various sulfated compounds were tested as
extractants; Fig. 1 illustrates that
heparin/heparan sulfates and chondroitin sulfates were effective
extractants at 0.2 mg/ml, but keratan sulfate showed only a weak
effect. Sulfated compounds such as pentosan polysulfate and suramin
also liberated TIMP-3, but higher concentrations (2 mg/ml) were
required (Fig. 1). Heat extraction, effective for matrilysin (2), was
much less so for TIMP-3. Two bands of TIMP-3 (27 and 22 kDa,
corresponding to glycosylated and nonglycosylated forms (22), appeared
in the reverse zymogram. Most of the TIMP-1 and TIMP-2 appeared in the
initial Triton extract (not shown). A band corresponding in position to
TIMP-2 was also extracted by GAGs, suramin, and pentosan (Fig. 1); this
may be TIMP-2 that was bound to gelatinase A, but positive
identification of the inhibitor has not been made. Heparin and suramin
also extracted a small inhibitory protein of 16 kDa that was not
sensitive to reduction/alkylation and has not been identified. Optimal
extraction of TIMP-3 was achieved at 2-4 mg of heparin/ml or 1-2 mg
of suramin/ml (not shown). A parallel gel was run on SDS-polyacrylamide
gel electrophoresis and stained with Coomassie Blue (right
portion of Fig. 1) to show that the dark bands interpreted as
TIMPs in the reverse zymograms were not due to nonspecific protein
bands. The intensity of the glycosylated TIMP-3 (T3*) band
appears to be less in the heparan sulfate/heparin lanes than in the
CS lanes. This is attributed to interaction with a
comigrating band of matrilysin extracted by heparin but not by
chondroitin sulfate; this protease band can be directly visualized in
the heat extract lane.

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 1.
Extraction of TIMP-3 from postpartum rat
uterus by sulfated compounds. Extract aliquots (10 µl) were
analyzed by reverse zymography as described under "Experimental
Procedures." The lanes contain: Mw, Marker 12 protein standards (Novex); T-3, authentic TIMP-3 marker from
University Technology International, Calgary. T3*,
glycosylated TIMP-3; R/A, reduced and alkylated to destroy
TIMP; CS-A, CS-B, CS-C, chondroitin
sulfates A, B, and C; All GAGS, extraction with heparin and
CS-A, -B, and -C combined. Left axis,
Mr values × 10 3. The gel to
the right serves as a control: samples were electrophoresed
in a gel without added gelatinase, held for 18 h at 4 °C and
stained together with the reverse zymogram. Coomassie Blue shows
intensity of the protein bands at each position.
|
|
TIMP-3 was identified by its position on the reverse zymogram and by
its sensitivity to destruction by reduction and alkylation (Fig.
2). A polyclonal antibody to human TIMP-3
(Santa Cruz) was used to show that heparin removed the factor from the
uterus (see Fig. 4 below), but the antibody proved unsuitable for
Western blotting of rat TIMP-3. Therefore, the identification of TIMP-3 depended on size, sensitivity to reduction and alkylation, and binding
to matrix as shown by loss from tissue sections following treatment
that increases TIMP-3 in reverse zymograms. TIMP-3 is the only TIMP
that binds to the extracellular matrix (5).

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 2.
Destruction of tissue TIMP-3 by reduction and
alkylation. Uterine extracts were prepared with 2 mg/ml suramin as
in Fig. 1, and 2-µl aliquots were applied to lanes 3 and
4; authentic TIMP-3 marker is in lane 2. The
sample in lane 4 (R/A) was first reduced and
alkylated to break disulfide bonds as described under "Experimental
Procedures."
|
|
Fig. 3 illustrates further extraction
studies; reverse zymography is not quantitative and permits only rough
qualitative comparisons. It was also affected by MMPs that migrated to
the same region and reacted with the TIMPs. The initial tissue extract
in Triton X-100 (normally discarded) contained some TIMP-3. This might
reflect binding of TIMP-3 to proteoglycans of the cell membranes, which were disrupted by Triton, or TIMP-3 in complex with gelatinase A and B
(23). SDS should have released the bulk of the inhibitor (based on its
ability to release the more tightly binding MMP-7 (2)), although some
might remain bound to MMP-2 through its hemopexin domain (23). The
highly positively charged heparin antagonist,
poly-D-lysine, extracted TIMP-3; it is suggested that it
competed with TIMP-3 for binding sites on the GAG chains. Digestion with chondroitinase ABC released less TIMP-3 than did heparinase III
digestion.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Heparinase III and chondroitinase ABC release
TIMP-3 from uterine tissue. Tissue was extracted in 0.25% Triton
X-100. Pellets were obtained by centrifugation and extracted
individually with 50 mM Tris buffer, 5 mg/ml
poly-D-lysine, or 2% SDS or incubated 18 h at
37 °C with 50 mM Tris buffer with protease inhibitors
(digest control), chondroitinase ABC, or heparinase III. Reverse
zymography was performed with 15 µl of each extract. Details are
given under "Experimental Procedures." rT3, recombinant
mouse TIMP-3 marker. The intensities of inhibitory bands were measured
by scanning and image analysis (Ultra Violet Products Ltd.) and
expressed as arbitrary density units (ADU).
|
|
Confocal Microscopy--
The postpartum rat uterus contained both
heparan sulfate (Fig. 4A) and
TIMP-3 (Fig. 4B), which were largely localized near the
uterine lumen, in the epithelial cells, and in their underlying basement membrane. There was little of either molecule in the deep
stroma (right side of Fig. 4C).
Superimposition of images indicates colocalization of the two proteins
with some small patches of green remaining, perhaps on chondroitin
sulfate. Washing with heparin (Fig. 4E) completely
eliminated the TIMP-3 staining. Digestion with chondroitinase ABC gave
some reduction in TIMP staining (Fig. 4G); but a better
estimate of the chondroitinase-sensitive binding is probably provided
by the residual staining in Fig. 4I. Digestion with
heparinase III gave extensive losses of both heparan sulfate and TIMP-3
(Fig. 4, H and I). Both components were
completely removed by digestion with the two enzymes together (Fig. 4,
J and K). Incubation of sections without added
enzyme did not lead to significant losses of either component (not
shown).

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 4.
Confocal microscopy of postpartum rat
uterus. Microscopy and antibody staining are detailed under
"Experimental Procedures." A, section stained with
antibody to heparan sulfate; the uterine lumen is to the
left. B, same section stained with antibody to
TIMP-3. C, superimposed staining showing colocalization of
heparan sulfate and TIMP-3. D, section stained with heparan
sulfate antibody following a heparin wash. E, same section
stained for TIMP-3. F, section stained for heparan sulfate
following treatment with chondroitinase ABC. G, same section
stained for TIMP-3. H, section stained for heparan sulfate
following heparinase III treatment. I, same section stained
for TIMP-3. J, section (similar to that in H)
stained for heparan sulfate following combined treatment with
heparinase III and chondroitinase ABC. K, same section
stained for TIMP-3.
|
|
Properties of Full-length and C-terminally Truncated
TIMP-3--
In reverse zymography (Fig.
5A), mouse TIMP-3 activity
could be detected in BHK-TIMP-3 cells but not in the mock-transfected cell line. Two forms of TIMP-3 were found in the medium: a 27-kDa form,
corresponding to the glycosylated form (24) and a 22-kDa nonglycosylated form. To see TIMP-3 in the medium, it was necessary to
culture for several days, presumably until binding sites in the ECM are
first filled. The denatured truncated human N-TIMP-3 (~14 kDa) was
prepared from E. coli and folded ("Experimental Procedures"). Similar amounts of protein were found before and after
folding (Fig. 5B) but only the folded form was inhibitory (Fig. 5C).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 5.
Expression of recombinant mouse TIMP-3 in
mammalian BHK cells and C-terminally truncated human N-TIMP-3 in
E. coli BL21(DE3) cells. A,
conditioned media (10 µl) from TIMP-3.BHK cells and mock-transfected
cells at 3 days culture were subjected to reverse zymography. The
expected molecular weights (22 and 27 kDa) of TIMP-3 activities
appeared only in the TIMP-3-transfected BHK cells. The 27-kDa band is
the glycosylated form. B, silver staining demonstrating the
purity of N-terminal TIMP-3. R, folded N-TIMP-3;
D, denatured, prior to folding. C, reverse
zymography showing the inhibitory activity of folded versus
denatured N-TIMP-3, together with full-length markers. 10 ng of
N-TIMP-3 was applied to each lane in B and
C.
|
|
Culture medium containing recombinant mouse TIMP-3 was mixed with
heparin-agarose beads and packed in a small column (see "Experimental
Procedures"). The initial concentration of NaCl was 0.15 M and the wash was with 0.2 M. Stepwise
increases in salt concentration eluted TIMP-3 between 0.3 and 0.8 M NaCl, with the peak at about 0.5 M (Fig.
6A). Both the glycosylated and
unglycosylated forms emerged at the same position. Further washing with
2% SDS removed a small amount of residual TIMP (about 5%). The
purified and folded human N-TIMP-3 bound in similar fashion (Fig.
6B); both monomeric and dimeric forms were eluted with a
peak also around 0.5 M NaCl but with somewhat longer
tailing. This tailing, with a distinct band at 0.9 M NaCl
was attributed to the propensity of the truncated TIMP to aggregate.
Such aggregates may be eluted at higher salt, but the aggregates did
not appear on the gel because of dissociation by SDS in the gel. The
elution of full-length and truncated TIMP-3 around 0.5 M
NaCl indicated that the major heparin binding site was located in the
N-terminal part of the protein.

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 6.
Binding of recombinant mouse TIMP-3 to
heparin-agarose. A, the BHK-TIMP-3-conditioned medium
was bound to heparin-agarose beads and eluted from a column as
described under "Experimental Procedures." Eluted fractions were
applied to reverse zymography. Mw, Marker 12; S,
starting protein solution; F, fall through; W,
wash; elution by stepwise increasing concentrations (0.2-1.0
M) of NaCl in Tris buffer, followed by two washes with 2%
SDS. B, recombinant N-TIMP-3 was applied to a similar
heparin column and eluted in the same way (omitting the 0.2 M NaCl step).
|
|
Three peptides were synthesized based on the A and B strand sequences
of rat TIMP-3 (25): Pep1 = residues 19-32
(IRAKVVGKKLVKEG); Pep2 = residues 41-52
(IKQMKMYRGFSKM);
and the spanning peptide Pep3 = residues 19-52
(IRAKVVGKKLVKEGPFGTLVYTIKQMKMYRFHSKM).
This last peptide contained 9 basic residues potentially involved in heparin binding. It can be seen from Fig.
7 that the two shorter peptides have
similar affinity for heparin and that this is about 10-fold less than
the binding affinity of the long peptide (IC50 = 3.5 µM). All three bound more firmly than the
RHAMM401-410 peptide
(KQKIKHVVKLK).
N-TIMP-3 was unstable under the reducing conditions of this assay and
could not be measured.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Characterization of putative heparin-binding
peptides of TIMP-3 A and B strands by DNase II-based homogeneous
heparin-binding assay. Heparin (0.8 µg/ml) inhibited the assay
of 1.2 µM DNase II as described under "Experimental
Procedures." This inhibition of DNase II was reversed by adding the
synthetic peptides Pep1 ( ), Pep2 ( ), and Pep3 ( ) as
competitors for heparin; the sequences are given in the Text.
RHAMM401-411 ( ) is a positive control and BSA ( ) is
a negative control. The peptide sequences are given at the end of
"Results." All points were determined by triplicate assay.
|
|
 |
DISCUSSION |
There has been no systematic study of the extraction of TIMP-3
from the ECM. It was earlier noted that guanidine and SDS are effective
extractants (26). Here we show that negatively charged molecules
(heparin, various GAGs, and polysulfated compounds) gave extensive
extraction comparable to SDS, but positively charged compounds such as
polylysine were also extractants. However, enzymatic treatment with
heparinase III and chondroitinase ABC gave extensive extraction,
pointing to the negatively charged GAG molecules as binding sites, so
positively charged compounds such as polylysine probably competed with
TIMP-3 for binding to heparin. A preponderance of basic over acidic
residues (26:13) in TIMP-3 also supports this interpretation. It is
interesting to note that cultured mouse mesangial cells produce TIMP-3
in the medium only after pentosan polysulfate or heparin treatment
(27); we suggest this might be due to the release of TIMP-3 bound to
the ECM of the cultures.
The N-terminal domain of TIMP-3 contains 17 positive and 8 negative
charges (25) and exhibits the OB (oligosaccharide/oligonucleotide binding) fold (9). Because GAGs are similar in charge and
linearity to oligosaccharides/nucleotide polymers, the N-terminal
domain of TIMP-3 could be a binding site for GAGs. The binding of
TIMP-3 is strong, but not nearly as strong as the binding of
matrilysin: TIMP-3 is eluted from a heparin affinity column with 0.5 M NaCl, whereas matrilysin is not eluted at 2 M
NaCl (2). Matrilysin also has a great many more positive residues that
might participate in binding. The fact that chondroitinase ABC appeared
to release TIMP-3 from tissue but not as efficiently as heparinase III
(Figs. 3 and 4) suggests that the binding is not highly specific.
Several types of sulfated GAGs may serve as binding sites, but heparan sulfate chains are probably the major sites. Full-length TIMP-3 eluted
from a heparin affinity column at 0.5 M NaCl. This matches exactly the results of Butler et al. (23); they also showed that TIMP-1 and TIMP-2 did not bind to heparin at 0.15 M
NaCl, supporting our hypothesis that TIMP-3 is distinctive in binding to heparin. They further showed that glycosylation at the site Asn184 near the C terminus has no effect on binding and
elution, comparable to the results in Fig. 6. We found that the
N-domain of TIMP-3 bound to heparin with affinity similar to that of
full-length TIMP-3, indicating that most of the free energy of binding
is contributed by the N terminus. It must be mentioned that our results are not in agreement with those of Langton et al. (22) who
expressed the N-domain of human TIMP-3 in COS-7 cells. In that case,
full-length TIMP-3 bound to the ECM produced by the COS cells, whereas
the N-domain did not and adding the N-domain of TIMP-2 to the C-domain of TIMP-3 gave partial but not full binding. We cannot explain this
contradictory finding except to suggest that COS cells may make a
different ECM than other cells.
The three-dimensional structure of TIMP-3 is not known but is assumed
to be similar to that of TIMP-1 and TIMP-2; for both cases we know the
complete x-ray crystallographic structure (9, 28) and the NMR structure
of the N-domain (29, 30). In these two structures there are two
-strands, A and B, within the first disulfide-bonded loop. These
strands lie across the protein surface and remain exposed when TIMP
binds to MMPs. Fig. 8 shows models of the
A and B strands (plus 5 further residues) of human TIMP-3 based on
human TIMP-1 and -2. We have focused on this region, because its
sequence is quite distinct from that of the A and B strands of the more
readily soluble TIMP-1 and TIMP-2. This region contains 9 basic
residues and only 1 acidic residue (Glu30), which is
directed downward and interacts with Lys89 (not shown).
TIMP-1 has only 6 basic residues and 3 acidic, and TIMP-1, although it
also has 9 basic residues, has 7 acidic residues. So, only TIMP-3 has a
large excess of positive charge in this region, which might explain its
unique matrix-binding property. In both models (Fig. 8) 6 basic
residues are directed upward from the surface and 3 are lying on the
surface where they are H-bonded to nearby residues. However, these 3 might also contact a heparin chain if their H-bonds were disrupted.
There is a tendency for the basic residues to form a double track,
which might interact with sulfate groups attached to alternate sides of
the heparin backbone. Either model would predict that a single chain of
heparin/heparan sulfate would be stretched along the TIMP surface and
contacting, at a minimum, Lys30, Lys26,
Lys22, Lys42, Arg20, and
Lys45, with additional basic residues possibly joining
through an induced fit effect.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 8.
Model of the A and B strands of TIMP-3 based
on the coordinates of TIMP-2. The 2.8-Å x-ray coordinates
for human TIMP-1 (Ref. 9, PDB no. 1UEA) and 2.1-Å coordinates for
human TIMP-2 (Ref. 25, PDB no. 1BR9) were used as templates for
modeling the sequence of TIMP-3 by use of the program Swiss-Model. The
resultant coordinates were then subjected to energy minimization using
the Polak-Ribiere algorithm in HYPERCHEM to a root mean square gradient
of 0.01 kcal/Å mol, with a MM+ force field. The resultant
coordinates were then displayed for the A and B strands and the
connecting AB loop by use of the MOLSCRIPT program. The backbone is
shown in green with red designating parts of the
strand that are -sheet-like. Arg and Lys residues are shown in
ball-and-stick representation with nitrogen in
blue. The view is from the side, with the two strands
marking the surface of the molecule.
|
|
This study has included human, rat, and mouse TIMP-3. It is reasonable
to expect them all to bind to heparin in an almost identical fashion.
In the entire N-domain, there are only 3 amino acid differences between
human and rat/mouse and none involving the basic and acidic residues.
The data from rat uterus indicate that TIMP-3 is produced in large
amount in the postpartum uterus and that it is colocalized to a great
extent with heparan sulfate. Both compounds occur in the epithelium and
upper stroma and not in the deeper stroma of the endometrium. At the
same time in involution, the uterus is also producing a high level of
matrilysin in the epithelial cells around the lumen. One role of TIMP-3
might be to regulate the matrilysin activity so that it does not attack the immediately underlying stroma. In this respect, it is interesting that matrilysin plays a role in protection against bacterial infection. In the intestine, this takes the form of activating precursors of
-defensin peptides with bactericidal activity (31). It is possible
that a similar defense role is played in the postpartum uterus, which
would be quite susceptible to infection, and that TIMP-3 would be an
important regulator of this process.
Why would TIMP-3 be firmly bound to the ECM, whereas the other TIMPs
are relatively soluble? Anand-Apte et al. (32) have suggested several reasons, based on the ability of TIMP-3 to suppress growth of tumors when melanoma cells are transfected with TIMP-3. First, the deposition of TIMP-3 in the surrounding matrix may prevent
local expansion of the tumor by blocking MMP activity. Second, TIMP-3
may retard the release of sequestered growth factors, needed for tumor
growth, from the ECM. Third, the protein may inhibit angiogenesis,
preventing adequate blood supply to the tumor.
The anti-adhesive property of TIMP-3 has been observed in fibroblast
cells (33), and this might sensitize the anoikis processes. Interestingly, whereas TIMP-1 and -2 are known for their growth effects
(5), overexpression of TIMP-3 can induce apoptosis in melanoma cells
(34) and smooth muscle cells (35). In certain cell types such as
melanoma, smooth muscle, MCF-7, and HT109 cells overexpression of
TIMP-3, but not of TIMP-1 or TIMP-2, promotes entry into the cell
cycle, which could lead to induction of apoptosis (36), and stabilizes
pro-apoptotic surface molecules such as tumor necrosis factor-
receptor (37). It has been shown that TIMP-3 added exogenously to cell
culture can induce apoptosis by extracellular action and that this
effect is not due to inhibition of matrix metalloproteinases as shown
by the lack of effect of the inhibitor BB-94 (36). Finally, many
GAG chains are part of proteoglycan molecules attached to the cell
surface; TIMP-3 bound in this location would be well-positioned to
inhibit the shedding of tumor necrosis factor- (10) and the
syndecans 1 and 4 (38).
 |
ACKNOWLEDGEMENT |
We thank Tristan Fiedler for the preparation
of Fig. 8.
 |
FOOTNOTES |
*
This research was supported by United States Public Health
Services Grants AR-40994 (to K. B.) and AR-16940 (to J. F. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Molecular Pathology Unit, Dept. of Pathology,
Massachusetts General Hospital, Harvard Medical School, 149 13th
St, 7th Floor, Charlestown, MA 02129.
§
Present address: Roche Molecular Systems, Inc., 4300 Hacienda Dr.,
Pleasanton, CA 94588.
¶
To whom correspondence should be addressed: Dept. of
Biochemistry and Molecular Biology, University of Miami School of
Medicine, R-127, P.O. Box 106960, Miami, FL 33101. Tel.: 305-243-6510;
Fax: 305-243-3955; E-mail: fwoessne@med.miami.edu.
Published, JBC Papers in Press, July 18, 2000, DOI 10.1074/jbc.M000907200
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular
matrix;
GAG, glycosaminoglycan;
MMP, matrix metalloproteinase;
PBS, phosphate-buffered saline;
TIMP, tissue inhibitor of
metalloproteinases;
N-TIMP-3, N-terminal domain of TIMP-3;
BHK, baby
hamster kidney.
 |
REFERENCES |
| 1.
|
Iozzo, R. V.
(1998)
Ann. Rev. Biochem.
67,
609-652
|
| 2.
|
Yu, W.-H.,
and Woessner, J. F., Jr.
(2000)
J. Biol. Chem.
275,
4183-4191
|
| 3.
|
Nagase, H.,
and Woessner, J. F., Jr.
(1999)
J. Biol. Chem.
274,
21491-21494
|
| 4.
|
Massova, I.,
Kotra, L. P.,
Fridman, R.,
and Mobashery, S.
(1998)
FASEB J.
12,
1075-1095
|
| 5.
|
Gomez, D. E.,
Alonso, D. F.,
Yoshiji, H.,
and Thorgeirsson, U. P.
(1997)
Eur. J. Cell Biol.
74,
111-122
|
| 6.
|
Burger, D.,
Rezzonico, R.,
Li, J. M.,
Modoux, C.,
Pierce, R. A.,
Welgus, H. G.,
and Dayer, J. M.
(1998)
Arthritis Rheum.
41,
1748-1759
|
| 7.
|
Murate, T.,
and Hayakawa, T.
(1999)
Platelets
10,
5-16
|
| 8.
|
Andreu, T.,
Beckers, T.,
Thoenes, E.,
Hilgard, P.,
and von Melchner, H.
(1998)
J. Biol. Chem.
273,
13848-1385
|
| 9.
|
Gomis-Rüth, F. X.,
Maskos, K.,
Betz, M.,
Bergner, A.,
Huber, R.,
Suzuki, K.,
Yoshida, N.,
Nagase, H.,
Brew, K.,
Bourenkov, G. P.,
Bartunik, H.,
and Bode, W.
(1997)
Nature
389,
77-81
|
| 10.
|
Murphy, G.,
Houbrechts, A.,
Cockett, M. I.,
Williamson, R. A. O.,
O'Shea, M.,
and Docherty, A.
(1991)
Biochemistry
30,
8097-8102
|
| 11.
|
Blenis, J.,
and Hawkes, S. P.
(1984)
J. Biol. Chem.
259,
11563-11570
|
| 12.
|
Pavloff, N.,
Staskus, P. W.,
Kishnani, N. S.,
and Hawkes, S. P.
(1992)
J. Biol. Chem.
267,
17321-17326
|
| 13.
|
Amour, A.,
Slocombe, P. M.,
Webster, A.,
Butler, M.,
Knight, C. G.,
Smith, B. J.,
Stephens, P. E.,
Shelley, C.,
Hutton, M.,
Knäuper, V.,
Docherty, A. J. P.,
and Murphy, G.
(1998)
FEBS Lett.
435,
39-44
|
| 14.
|
Smith, M. R.,
Kung, H. F.,
Durum, S. K.,
Colburn, N. H.,
and Sun, Y.
(1997)
Cytokine
9,
770-780
|
| 15.
|
Borland, G.,
Murphy, G.,
and Ager, A.
(1999)
J. Biol. Chem.
274,
2810-2815
|
| 16.
|
Hargreaves, P. G.,
Wang, F. F.,
Antcliff, J.,
Murphy, G.,
Lawry, J.,
Russell, R. G. G.,
and Croucher, P. I.
(1998)
Br. J. Haematol.
101,
694-702
|
| 17.
|
Fariss, R. N.,
Apte, S. S.,
Luthert, P. J.,
Bird, A. C.,
and Milam, A. H.
(1998)
Br. J. Ophthalmol.
82,
1329-1334
|
| 18.
|
Yang, T. T.,
and Hawkes, S. P.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10676-10680
|
| 19.
|
Apte, S. S.,
Hayashi, K.,
Seldin, M. F.,
Mattei, M. G.,
Hayashi, M.,
and Olsen, B. R.
(1994)
Dev. Dyn.
200,
177-197
|
| 20.
|
Weeks, J. G.,
Halme, J.,
and Woessner, J. F., Jr.
(1976)
Biochim. Biophys. Acta
445,
205-214
|
| 21.
|
Guo, X.,
Han, I. S.,
Yang, V. C.,
and Meyerhoff, M. E.
(1996)
Anal. Biochem.
235,
153-160
|
| 22.
|
Langton, K. P.,
Barker, M. D.,
and McKie, N.
(1998)
J. Biol. Chem.
273,
16778-16781
|
| 23.
|
Butler, G. S.,
Apte, S. S.,
Willenbrock, F.,
and Murphy, G.
(1999)
J. Biol. Chem.
274,
10846-10851
|
| 24.
|
Apte, S. S.,
Olsen, B. R.,
and Murphy, G.
(1995)
J. Biol. Chem.
270,
14313-14318
|
| 25.
|
Douglas, D. A.,
Shi, Y. E.,
and Sang, Q. X. A.
(1997)
J. Protein Chem.
16,
237-255
|
| 26.
|
Breedveld, F. C.
(1997)
Arthritis Rheum.
40,
794-796
|
| 27.
|
Elliot, S. J.,
Striker, L. J.,
Stetler-Stevenson, W. G.,
Jacot, T. A.,
and Striker, G. E.
(1999)
J. Am. Soc. Nephrol.
10,
62-68
|
| 28.
|
Tuuttila, A.,
Morgunova, E.,
Bergmann, U.,
Lindqvist, Y.,
Maskos, K.,
Fernandez-Catalan, C.,
Bode, W.,
Tryggvason, K.,
and Schneider, G.
(1998)
J. Mol. Biol.
284,
1133-1140
|
| 29.
|
Williamson, R. A.,
Martorell, G.,
Carr, M. D.,
Murphy, G.,
Docherty, A. J. P.,
Freedman, R. B.,
and Feeney, J.
(1994)
Biochemistry
33,
11745-11759
|
| 30.
|
Williamson, R. A.,
Natalia, D.,
Gee, C. K.,
Murphy, G.,
Carr, M. D.,
and Freedman, R. B.
(1996)
Eur. J. Biochem.
241,
476-483
|
| 31.
|
Wilson, C. L.,
Ouellette, A. J.,
Satchell, D. P.,
Ayabe, T.,
López-Boado, Y. S.,
Stratman, J. L.,
Hultgren, S. J.,
Matrisian, L. M.,
and Parks, W. C.
(1999)
Science
286,
113-117
|
| 32.
|
Anand-Apte, B.,
Bao, L.,
Smith, R.,
Iwata, K.,
Olsen, B. R.,
Zetter, B.,
and Apte, S. S.
(1996)
Biochem. Cell Biol.
74,
853-862
|
| 33.
|
Blenis, J.,
and Hawkes, S. P.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
770-774
|
| 34.
|
Ahonen, M.,
Baker, A. H.,
and Kahari, V. M.
(1998)
Cancer Res.
58,
2310-2315
|
| 35.
|
Baker, A. H.,
Zaltsman, A. B.,
George, S. J.,
and Newby, A. C.
(1998)
J. Clin. Invest.
101,
1478-1487
|
| 36.
|
Baker, A. H.,
George, S. J.,
Zaltsman, A. B.,
Murphy, G.,
and Newby, A. C.
(1999)
Br. J. Cancer
79,
1347-1355, 1999
|
| 37.
|
Smith, M. R.,
Kung, H. F.,
Durum, S. K.,
Colburn, N. H.,
and Sun, Y.
(1997)
Cytokine
9,
770-780
|
| 38.
|
Fitzgerald, M. L.,
Wang, Z.,
Park, P. W.,
Murphy, G.,
and Bernfield, M.
(2000)
J. Cell Biol.
148,
811-824
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Troeberg, K. Fushimi, R. Khokha, H. Emonard, P. Ghosh, and H. Nagase
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases
FASEB J,
October 1, 2008;
22(10):
3515 - 3524.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. G. Stetler-Stevenson
Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities
Sci. Signal.,
July 8, 2008;
1(27):
re6 - re6.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-H. Kang, S.-Y. Park, S. B. Rho, and J.-H. Lee
Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis
Cardiovasc Res,
July 1, 2008;
79(1):
150 - 160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Wayne, S.-J. Deng, A. Amour, S. Borman, R. Matico, H. L. Carter, and G. Murphy
TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4
J. Biol. Chem.,
July 20, 2007;
282(29):
20991 - 20998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. V. Hojilla, I. Kim, Z. Kassiri, J. E. Fata, H. Fang, and R. Khokha
Metalloproteinase axes increase beta-catenin signaling in primary mouse mammary epithelial cells lacking TIMP3
J. Cell Sci.,
March 15, 2007;
120(6):
1050 - 1060.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-H. Lee, S. Atkinson, and G. Murphy
Identification of the Extracellular Matrix (ECM) Binding Motifs of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Effective Transfer to TIMP-1
J. Biol. Chem.,
March 2, 2007;
282(9):
6887 - 6898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Verstappen and J.W. Von den Hoff
Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease
Journal of Dental Research,
December 1, 2006;
85(12):
1074 - 1084.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M A Majid, V A Smith, F J Matthews, A C Newby, and A D Dick
Tissue inhibitor of metalloproteinase-3 differentially binds to components of Bruch's membrane
Br. J. Ophthalmol.,
October 1, 2006;
90(10):
1310 - 1315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.-J. Oh, J. L. Martin, A. J. Williams, P. Russell, D. E. Birk, and D. J. Rhee
Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells.
Invest. Ophthalmol. Vis. Sci.,
September 1, 2006;
47(9):
3887 - 3895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Plumb, S McQuaid, A K Cross, J Surr, G Haddock, R A. Bunning, and M N Woodroofe
Upregulation of ADAM-17 expression in active lesions in multiple sclerosis
Multiple Sclerosis,
August 1, 2006;
12(4):
375 - 385.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G Haddock, A K Cross, J Plumb, J Surr, D J Buttle, R A. Bunning, and M N Woodroofe
Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter
Multiple Sclerosis,
August 1, 2006;
12(4):
386 - 396.
[Abstract]
[PDF]
|
| |